This article first appeared on GuruFocus .

• Fundraising:EUR105 million raised in December 2025.

• Debt Conversion:EUR39 million debt converted into equity, making the company virtually debt-free.

• Cash Burn:Approximately EUR38.2 million in 2025.

• Financial Visibility:Funding secured until early 2028.

Release Date: March 24, 2026

• Warning! GuruFocus has detected 9 Warning Signs with STU:TGNA.

• Is STU:TGNA fairly valued? Test your thesis with our free DCF calculator.

For the complete transcript of the earnings call, please refer to the full earnings call transcript .

Positive Points

• Transgene SA ( STU:TGNA ) presented compelling clinical and translational data for their myvac platform, particularly in head and neck cancer, reinforcing its potential to prevent relapse.

• The company successfully raised EUR105 million, providing financial visibility until the first quarter of 2028, which supports their priority programs.

• Phase I data showed a 100% disease-free survival rate for patients with HPV-negative cancer treated with TG4050, indicating its potential effectiveness.

• Transgene SA is actively optimizing its manufacturing process to improve turnaround time and prepare for increased production volumes.

• The company is virtually debt-free after converting EUR39 million of debt into equity, strengthening its balance sheet.

Negative Points

• The company's progress is subject to multiple risks and uncertainties, as highlighted in their forward-looking statements.

• The competitive landscape in cancer treatment is changing, which may impact the company's strategic decisions and trial outcomes.

• The success of the myvac platform and TG4050 is still dependent on future clinical trial results, including the upcoming Phase II data.

• There is uncertainty regarding the timing and approval of new trials, as regulatory feedback is still pending for some initiatives.

• The company's future success is contingent on attracting interest from pharmaceutical partners, which is not guaranteed.

Q & A Highlights

Q: How should we be looking at the 3-year DFS data that are approaching in Q2, Q3, given that the primary endpoint and the benchmark are two years? And what do you expect to see here? A: Alessandro Riva, CEO: We plan to submit an abstract for the conference in Q3 2026. The base case scenario is that the two curves stay separated throughout the additional follow-up. The best-case scenario would show a larger magnitude of separation, indicating a more significant benefit for patients. The worst-case scenario would be observing relapses in the TG4050 arm.